Clinical Trial Update: Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial investigating RHB-104 as add-on to interferon beta-1a in relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• RHB-104

Snippet

Sponsor: RedHill Biopharma Limited | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED